Market Overview

UPDATE: Stifel Upgrades Clovis Oncology On Favorable Risk/Reward


In a report published Thursday, Stifel analyst Brian Klein upgraded the rating on Clovis Oncology (NASDAQ: CLVS) from Hold to Buy, and named a $50.00 price target.

In the report, Stifel noted, “Following the significant pull-back of ~60% from recent highs, we believe Clovis now presents with significant upside potential based on clinical and commercial prospects for CO-1686 in second-line EGFR-mutant NSCLC with T790M mutation. While we still remain conservative on approval timing and potential in earlier-stage disease, and note safety/tolerability concerns (particularly hyperglycemia), we view '1686 as a compelling and commercially viable, clinical candidate.

"We derive a compelling target price based on usage in the T790M population alone and note that additional '1686 indications as well as clinical success for other pipeline candidates could provide further upside.”

Clovis Oncology closed on Wednesday at $38.40.

Latest Ratings for CLVS

Nov 2020SVB LeerinkMaintainsUnderperform
Nov 2020HC Wainwright & Co.MaintainsBuy
May 2020HC Wainwright & Co.ReiteratesBuy

View More Analyst Ratings for CLVS
View the Latest Analyst Ratings


Related Articles (CLVS)

View Comments and Join the Discussion!

Posted-In: Brian Klein StifelAnalyst Color Upgrades Analyst Ratings

Latest Ratings

PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at